| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 10g |
|
||
| 1kg |
|
||
| Other Sizes |
| Targets |
Tryptamine targets multiple receptors and transporters. It is an agonist of hTAAR1 (human trace amine-associated receptor 1). The compound acts as a non-selective serotonin receptor agonist and a serotonin-norepinephrine-dopamine releasing agent (SNDRA). It activates G protein-coupled receptors (GPCRs) to promote intestinal anion secretion. Tryptamine is a biochemical precursor to serotonin, melatonin, and various psychedelic substances.
|
|---|---|
| ln Vitro |
In vitro, Tryptamine acts as an hTAAR1 agonist and a non-selective serotonin receptor agonist. It promotes intestinal anion secretion and fluid transport by activating GPCRs. The compound is a neuromodulator that modulates mood, cognition, and perception. Its receptor binding and functional activities have been characterized in various in vitro systems.
|
| ln Vivo |
In vivo, Tryptamine promotes intestinal anion secretion and fluid transport, accelerating gastrointestinal motility. It can be used to study intestinal motility disorders such as functional constipation. The compound has shown significant efficacy in multiple sclerosis models. Tryptamine is a biochemical precursor to serotonin, melatonin, and psychedelic substances.
|
| Enzyme Assay |
In vitro receptor binding assays for Tryptamine involve measuring affinity for hTAAR1 and serotonin receptors. Radioligand binding displacement studies are performed using membranes from cells expressing these receptors. Functional activity is assessed by measuring receptor-mediated signaling such as cAMP changes or calcium mobilization. For SNDRA activity, neurotransmitter release is measured. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for Tryptamine are conducted in cells expressing hTAAR1, serotonin receptors, or GPCRs. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Receptor activation is assessed by measuring cAMP or calcium signaling. For intestinal studies, intestinal epithelial cells are used and anion secretion is measured. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Tryptamine in vivo studies are conducted in animal models of intestinal motility disorders and multiple sclerosis. Animals are treated with Tryptamine via oral administration or injection. Gastrointestinal motility is assessed by measuring intestinal transit. For multiple sclerosis models, disease progression and immune responses are assessed. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Tryptamine (MW 160.22 g/mol, C10H12N2) is a monoamine alkaloid with an indole ring structure. It is a neuromodulator and neurotransmitter. The compound is soluble in organic solvents. It is stable under recommended storage conditions. Tryptamine is an hTAAR1 agonist and SNDRA. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Tryptamine is generally well-tolerated in preclinical studies. The compound is a monoamine alkaloid and neuromodulator. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Tryptamine is an aminoalkylindole, composed of an indole molecule with a 2-aminoethyl group linked at the 3-position. It is found in humans, plants, and mice as a metabolite. Tryptamine belongs to the aminoalkylindole, indole alkaloid, and arylalkylamino compound class, and is also a type of Tryptamine compound. It is the conjugate base of Tryptamine. Tryptamine has been reported to exist in Polygala tenuifolia, Rauvolfia serpentina, and other organisms with relevant data.
Tryptamine is a monoamine alkaloid found in animals, plants, and fungi that functions as a neuromodulator and neurotransmitter. It is an hTAAR1 agonist and a non-selective serotonin receptor agonist and SNDRA. The compound promotes intestinal anion secretion and accelerates gastrointestinal motility. It is a biochemical precursor to serotonin, melatonin, and psychedelic substances. Its molecular formula is C10H12N2 with a molecular weight of 160.22 g/mol.All applications are limited to non-human research use. |
| Molecular Formula |
C10H12N2
|
|---|---|
| Molecular Weight |
160.2157
|
| Exact Mass |
160.1
|
| CAS # |
61-54-1
|
| Related CAS # |
343-94-2 (mono-hydrochloride);34685-69-3 (unspecified sulfate)
|
| PubChem CID |
1150
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
378.8±0.0 °C at 760 mmHg
|
| Melting Point |
113-116 °C(lit.)
|
| Flash Point |
187.7±8.1 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.669
|
| Source |
Originated from microorganisms
Endogenously produced metabolite |
| LogP |
1.38
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
147
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NCCC1=CNC2=C1C=CC=C2
|
| InChi Key |
APJYDQYYACXCRM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H12N2/c11-6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6,11H2
|
| Chemical Name |
2-(1H-indol-3-yl)ethanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 150 mg/mL (~936.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2414 mL | 31.2071 mL | 62.4142 mL | |
| 5 mM | 1.2483 mL | 6.2414 mL | 12.4828 mL | |
| 10 mM | 0.6241 mL | 3.1207 mL | 6.2414 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
